Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity
CONCLUSION: The concurrent use of radiotherapy, pertuzumab and trastuzumab is feasible with good tolerance. Larger prospective data with longer follow-up is needed to confirm these results.PMID:33771453 | DOI:10.1016/j.canrad.2020.06.037
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: S Ben Dhia P Loap D Loirat A Vincent-Salomon K Cao L Escalup A Fourquet Y Kirova Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Dermatitis | Dermatology | Docetaxel | HER2 | Herceptin | Neurology | Palliative | Radiation Therapy | Study | Taxotere | Toxicology